|Bid||0.0000 x 100|
|Ask||6,229.8701 x 100|
|Day's range||0.0000 - 0.0000|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||0.00|
|Earnings date||01 Feb 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.